<DOC>
	<DOC>NCT00600990</DOC>
	<brief_summary>The purpose of this study is to determine the effectiveness of this medication in preventing nausea and vomiting in female patients at risk for post-operative nausea and vomiting (PONV).</brief_summary>
	<brief_title>Study Of An NK-1 Anti-Emetic Medication For The Prevention Of Post-Operative Nausea And Vomiting In Female Patients</brief_title>
	<detailed_description>A Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Group, Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Oral (25 mg) and Intravenous (3 mg and 18 mg) Formulations of the Neurokinin-1 Receptor Antagonist, GW597599, When Administered with Intravenous Ondansetron Hydrochloride for the Prevention of Post-operative Nausea and Vomiting and Post-discharge Nausea and Vomiting in Female Subjects with Known Risk Factors for PONV Who are Undergoing Surgical Procedures Associated with an Increased Emetogenic Risk</detailed_description>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Postoperative Nausea and Vomiting</mesh_term>
	<mesh_term>Vestipitant</mesh_term>
	<criteria>known risk factors for PONV. Undergoing gynecological or gallbladder surgery.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>post-operative nausea and vomiting</keyword>
	<keyword>PONV</keyword>
</DOC>